Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Lonza Group Ag (LZAGY : OTC)
 
 • Company Description   
Lonza Group AG operates as a supplier to the pharmaceutical, healthcare and life-science industries. The Company divides its activities into four divisions: Life Science Ingredients; Microbial Control; Custom Manufacturing, and Bioscience. The company's Life Science Ingredients segment produces nutrition ingredients for applications in nutrition (food, feed and pharmaceutical application) and chemical intermediates for the agricultural industry. The Microbial Control division focuses on five areas: hygiene, wood protection, water treatment, oil/gas applications, and industrial preservation and comprises products ranging from disinfectants to household cleaning products. The Custom Manufacturing division comprises products used in pharmaceuticals sector. The Bioscience division comprises bioscience products, including cell culture and molecular biology tools for research, tests for microbial detection, and media used in the production of therapeutics. Lonza Group AG is headquartered in Basel, Switzerland.

Number of Employees: 18,000

 
 • Price / Volume Information   
Yesterday's Closing Price: $70.07 Daily Weekly Monthly
20 Day Moving Average: 83,352 shares
Shares Outstanding: 722.26 (millions)
Market Capitalization: $50,608.90 (millions)
Beta: 1.16
52 Week High: $73.29
52 Week Low: $55.80
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 2.77% -2.79%
12 Week 10.66% -7.16%
Year To Date 19.21% 11.66%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
Muenchensteinerstrasse 38
-
Basel,V8 4002
CHE
ph: 41-61-316-8111
fax: 41-61-316-9111
investor.relations@lonza.com http://www.lonza.com
 
 • General Corporate Information   
Officers
Pierre-Alain Ruffieux - Chief Executive Officer
Albert M. Baehny - Chairman of the Board
Christoph Mader - Vice-Chairman of the Board
Philippe Deecke - Chief Financial Officer
Caroline Barth - Chief Human Resources Officer

Peer Information
Lonza Group Ag (BJCT)
Lonza Group Ag (CADMQ)
Lonza Group Ag (APNO)
Lonza Group Ag (UPDC)
Lonza Group Ag (IMTIQ)
Lonza Group Ag (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 54338V101
SIC: 2100
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding: 722.26
Most Recent Split Date: (:1)
Beta: 1.16
Market Capitalization: $50,608.90 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.15%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.11
Current Fiscal Year EPS Consensus Estimate: $1.94 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 15.47% Last Dividend Paid: 05/14/2025 - $0.11
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 36.19
Trailing 12 Months: -
PEG Ratio: 2.34
Price Ratios
Price/Book: 4.75
Price/Cash Flow: 34.97
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -
12/31/24 - -
Current Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - 1.52
Quick Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - 1.04
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - 11.47
Book Value
06/30/25 - -
03/31/25 - -
12/31/24 - 14.76
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - 2.60
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - 0.45
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - 31.12
 

Powered by Zacks Investment Research ©